

## **ACTIVITY DISCLOSURE STATEMENT**

## Clinical Approach to Vascular Ultrasound and Registered Physician in Vascular Interpretation (RPVI) Prep Course

734797-2402 June 14 – 15, 2024

## Accreditation

In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## **Physician Accreditation**

The Harvard Medical School designates this live activity for a maximum of 15.75 *AMA PRA Category 1 Credits* TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The following planners, speakers, and content reviewers have reported relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated:

NAME Course Planners:	COMPANY	RELATIONSHIP
Anahita Dua, MD, MBA, MS	Boston Scientific Medtronic Penumbra	Speaker Speaker Speaker
Course Faculty:		
John Carson, MD	Boston Scientific	Speaker
Traci B. Fox, MS, RT(R), RDMS, RVT	USC Ultrasound	Speaker
Michael Jaff, MD	Boston Scientific Access Vascular Gilde Healthcare Heartbeam	Employee Board of Trustees Consultant Board of Trustees
Ido Weinberg, MD	Magneto Thrombectomy Solutions Penumbra Inc.	Consultant Consultant

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.